Zhang H, Zeng S, Wu Y, Zhang R, Liu L, Xue Q
Biomed Opt Express. 2023; 14(7):3610-3621.
PMID: 37497492
PMC: 10368033.
DOI: 10.1364/BOE.493538.
Castillo-Rodriguez R, Palencia G, Anaya-Rubio I, Perez J, Jimenez-Farfan D, Escamilla-Ramirez A
J Cancer. 2021; 12(19):5693-5711.
PMID: 34475984
PMC: 8408120.
DOI: 10.7150/jca.59769.
Li M, Wang J, Song J, Shen F, Song L, Ni X
Biomed Res Int. 2021; 2021:8298737.
PMID: 33681380
PMC: 7925035.
DOI: 10.1155/2021/8298737.
Zhu W, Shi S, Yang Z, Song C, Shen J
World J Gastroenterol. 2020; 26(11):1208-1220.
PMID: 32231424
PMC: 7093309.
DOI: 10.3748/wjg.v26.i11.1208.
Cheung T, Han H, She W, Chen K, Chow P, Yoong B
Liver Cancer. 2018; 7(1):28-39.
PMID: 29662831
PMC: 5892359.
DOI: 10.1159/000481834.
Portal vein embolization in extended liver resection.
Narula N, Aloia T
Langenbecks Arch Surg. 2017; 402(5):727-735.
PMID: 28567528
DOI: 10.1007/s00423-017-1591-8.
Clinical utility of gadoxetate disodium-enhanced hepatic MRI for stereotactic body radiotherapy of hepatocellular carcinoma.
Nakamura Y, Kimura T, Higaki T, Honda Y, Komoto D, Yamagami T
Jpn J Radiol. 2015; 33(10):627-35.
PMID: 26227061
DOI: 10.1007/s11604-015-0465-7.
Functional gadoxetate disodium-enhanced MRI in patients with primary sclerosing cholangitis (PSC).
Hinrichs H, Hinrichs J, Gutberlet M, Lenzen H, Raatschen H, Wacker F
Eur Radiol. 2015; 26(4):1116-24.
PMID: 26205638
DOI: 10.1007/s00330-015-3913-y.
Preoperative estimation of future remnant liver function following portal vein embolization using relative enhancement on gadoxetic acid disodium-enhanced magnetic resonance imaging.
Sato Y, Matsushima S, Inaba Y, Sano T, Yamaura H, Kato M
Korean J Radiol. 2015; 16(3):523-30.
PMID: 25995681
PMC: 4435982.
DOI: 10.3348/kjr.2015.16.3.523.
Efficacy of liver parenchymal enhancement and liver volume to standard liver volume ratio on Gd-EOB-DTPA-enhanced MRI for estimation of liver function.
Yoneyama T, Fukukura Y, Kamimura K, Takumi K, Umanodan A, Ueno S
Eur Radiol. 2013; 24(4):857-65.
PMID: 24356768
DOI: 10.1007/s00330-013-3086-5.
Clinical factors predictive of insufficient liver enhancement on the hepatocyte-phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging in patients with liver cirrhosis.
Kim H, Choi J, Park C, Song M, Song D, Kim C
J Gastroenterol. 2013; 48(10):1180-7.
PMID: 23354621
DOI: 10.1007/s00535-012-0740-7.
Portal hypertension: contraindication to liver surgery?.
Capussotti L, Ferrero A, Vigano L, Muratore A, Polastri R, Bouzari H
World J Surg. 2006; 30(6):992-9.
PMID: 16736327
DOI: 10.1007/s00268-005-0524-9.
Management of hepatocellular carcinoma.
Cormier J, Thomas K, Chari R, Pinson C
J Gastrointest Surg. 2006; 10(5):761-80.
PMID: 16713550
DOI: 10.1016/j.gassur.2005.10.006.
Hepatectomy as treatment of choice for hepatocellular carcinoma in elderly cirrhotic patients.
Ferrero A, Vigano L, Polastri R, Ribero D, Lo Tesoriere R, Muratore A
World J Surg. 2005; 29(9):1101-5.
PMID: 16088422
DOI: 10.1007/s00268-005-7768-2.
Correlation between preoperative serum concentration of type IV collagen 7s domain and hepatic failure following resection of hepatocellular carcinoma.
Kubo S, Tsukamoto T, Hirohashi K, Tanaka H, Shuto T, Takemura S
Ann Surg. 2004; 239(2):186-93.
PMID: 14745326
PMC: 1356211.
DOI: 10.1097/01.sla.0000109152.48425.4d.
The prediction of portal pressure: a multivariate analysis of clinical data and intraoperative portal pressure.
Shimada M, Matsumata T, Itasaka H, Shirabe K, Taketomi A, Sugimachi K
Surg Today. 1994; 24(4):309-12.
PMID: 8038504
DOI: 10.1007/BF02348558.
Surgery for gastric carcinoma is feasible for patients over 80 years of age.
Korenaga D, Moriguchi S, Baba H, Kakeji Y, Orita H, Haraguchi M
World J Surg. 1991; 15(5):642-7; discussion 647-8.
PMID: 1949865
DOI: 10.1007/BF01789215.
[In situ protection of the liver with Bretschneider HTK solution].
Lamesch P, Raygrotzki S, Kehrer G, Gubernatis G, Ringe B, Evers B
Langenbecks Arch Chir. 1991; 376(2):85-92.
PMID: 1905377
DOI: 10.1007/BF01263465.
